Deep Dive Into Capricor Therapeutics Stock: Analyst Perspectives (5 Ratings)
Portfolio Pulse from Benzinga Insights
Capricor Therapeutics (NASDAQ:CAPR) has received mixed analyst ratings, with 3 bullish and 2 somewhat bullish ratings. Analysts have set a 12-month average price target of $23.0, with a high of $40.00 and a low of $8.00. The company's financial performance shows positive revenue growth but challenges in profitability and asset utilization.
September 20, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics has received mixed analyst ratings, with a majority being bullish. The average price target has slightly increased to $23.0. The company's financials show positive revenue growth but challenges in profitability and asset utilization.
The majority of analysts are bullish on CAPR, with a slight increase in the average price target, indicating positive sentiment. However, financial metrics show challenges in profitability and asset utilization, which could impact investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100